| Name | Company | Title | Industry | Location | Country | |
|---|---|---|---|---|---|---|
| Michael Landsittel | mla********@blueprintmedicines.com | Lengo Therapeutics | Chief Financial Officer | Biotechnology Research | Cambridge, MA, US | United States |
| Andy Boral | abo***@blueprintmedicines.com | Lengo Therapeutics | Executive Vice President, Clinical Development | Biotechnology Research | Cambridge, MA, US | United States |
| Jason Brubaker | jbr******@blueprintmedicines.com | Lengo Therapeutics | Vice President, Head of Medicinal Chemistry | Biotechnology Research | Cambridge, MA, US | United States |
| Philina Lee | ple*@blueprintmedicines.com | Lengo Therapeutics | Chief Commercial Officer | Biotechnology Research | Cambridge, MA, US | United States |
| Debbie Durso-Bumpus | ddu**********@blueprintmedicines.com | Lengo Therapeutics | Chief People Officer | Biotechnology Research | United States | United States |
| Helen Ho | [email protected] | Lengo Therapeutics | Chief Business Officer | Biotechnology Research | Cambridge, MA, US | United States |
| Tracey McCain | tmc****@blueprintmedicines.com | Lengo Therapeutics | Executive Vice President and Chief Legal Officer | Biotechnology Research | Cambridge, MA, US | United States |
| Ingrid Andrade | ian*****@blueprintmedicines.com | Lengo Therapeutics | Manager, Corporate Communications | Biotechnology Research | Cambridge, MA, US | United States |
| Sean Flanagan | sfl******@blueprintmedicines.com | Lengo Therapeutics | Vice President Sales | Biotechnology Research | Boston, MA, US | United States |
| Shuree Harrison | sha******@blueprintmedicines.com | Lengo Therapeutics | Vice President, Clinical Operations | Biotechnology Research | Cambridge, MA, US | United States |